TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03917576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral
Description: The resting heart rate (HRrest), maximum HR (HRmax), HR recovery (HRRTEST), delta HR recovery (ΔHRRTEST) were measured by continuous telemetric heart rate sensor (Polar FT4, PolarTM, Finland) during an incremental exercise test designed to obtain maximum oxygen consumption (VO2max) on a cycle ergometer (Lode Corival, Groningen, The Netherlands) similar with previous studies using similar cohort. An indirect calorimetry/ergospirometry system (Ultima CPXTM metabolic system, Medgraphics, Minnesota, USA) was used to measure VO2max until volitional exhaustion. Thus, the modified Astrand volitional protocol was applied in the participants of all NG, Pre-T2D and T2D groups increasing the load (i.e., Watts) 25 W each 2 min to women, and 50 W each 2 min to men.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training intervention
Description: Subjects also participated in a single HIIT session composed of 10-cycling intervals, using a Lode Corival cycle ergometer. The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at \~80-100 % maximal power achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training intervention
Description: Subjects also participated in a single HIIT session composed of 10-cycling intervals, using a Lode Corival cycle ergometer. The exercise session consisted of 1-minute cycling at high intensity (workload during each interval was set at \~80-100 % maximal power achieved during the incremental exercise test with a workload that allowed to work until the volitional muscle failure in 1-minute), followed by 2-minutes of inactive resting period (sitting still on the cycle ergometer), and was repeated 10 times (1x2x10 protocol; 1:2:10 to work:rest:repetitions respectively).
Study: NCT03934333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDA MDI 160/180 mcg
Description: Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDA MDI 160/180 mcg
Description: Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort Flexhaler 180 mcg
Description: Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmicort Flexhaler 180 mcg
Description: Pulmicort Flexhaler aerosol, power, single-dose given as 2 inhalations of 90 mcg.
Study: NCT04694820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text Message-Based Navigation Intervention
Description: Receive txt4TKI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03919682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Training, Phase 1
Description: Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Training, Phase 2
Description: Weeklong training in signs, symptoms and treatability of breast cancer, performance of clinical breast exam, and structured algorithms for management of breast complaints followed by regular mentorship for health center nurses. CHWs received a one-day training in breast awareness and how to educate communities about breast health.
Study: NCT00289952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: As per standard of care.
Study: NCT04001426

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The FemPulse System
Description: Non-invasive monitoring during activation of the FemPulse System
Study: NCT04301349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vaginal dinoprostone
Description: two tablets of vaginal dinoprostone (6 mg) 3 hours prior to IUD insertion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal misoprostol
Description: two tablets of vaginal misoprostol (400 mcg) 3 hours prior to IUD insertion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: two tablets of placebo given 3 hours prior to IUD insertion
Study: NCT01189396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A006
Description: Albuterol DPI with 180 mcg Albuterol/inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Placebo DPI with 0 mcg Albuterol/inhalation
Study: NCT03230682

Intervention type: DRUG
Intervention: antidepressant
Description: regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
Study: NCT01972269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL
Study: NCT03996577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
Study: NCT01189396

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proventil-HFA
Description: Albuterol MDI with 90 mcg Albuterol/inhalation
Study: NCT03061864

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Periviable Birth Plan
Study: NCT01296321

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Internet-administrated CBT-Treatment
Description: This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist
Description: Passive waitlist during 8-10 weeks.
Study: NCT02404792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity cardiovascular and resistance exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity cardiovascular and resistance exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cardiovascular and resistance exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity cardiovascular and resistance exercise
Study: NCT03491527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absolute isolation
Description: Absolute isolation with rubber dam
Study: NCT02800265

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Avmacol
Description: Avmacol is an over-the-counter mixture of broccoli seed and sprout extracts in tablet form to promote detoxification. These tablets contain natural substances that stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke.
Study: NCT00439374

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17 alpha-hydroxyprogesterone caproate
Description: Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oil
Description: Placebo oil is a 250 mg/mL solution of castor oil with benzyl benzoate and benzyl alcohol as a preservative
Study: NCT02128074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KRX-0502
Description: 1g tablets of KRX-0502
Study: NCT03301467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacopan
Description: Orally administered

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Avacopan Matching Placebo
Description: avacopan matching placebo
Study: NCT03841760

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET/CT
Description: For 18F-DCFPyL PET/CT: Approximately 9 mCi (333MBq) of 18F-DCFPyL is injected intravenously. Approximately 60-90 minutes following 18F-DCFPyL injection, CT and PET images are consecutively acquired from the base of the skull to the toes.~For 68Ga-PSMA-11 PET/CT: Approximately 2.5 MBq/kg (0.068 mCi/kg) of 68Ga-PSMA, up to a maximum of 300 MBq (8 mCi), is injected intravenously. Approximately 60 minutes following 68Ga-PSMA injection, CT and PET images are consecutively acquired from the base of the skull to toes.
Study: NCT01105377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entinostat
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03491527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Absolute isolation
Description: Absolute isolation with rubber dam

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation of the resin cement with MTA
Description: Manipulation of the resin cement with MTA according to the manufacturer's recommendations.
Study: NCT03157037

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Imlifidase
Description: One dose of 0.25 mg/kg body weight imlifidase on study day 1
Study: NCT00527319

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VT-122 low dose
Description: VT-122 low dose, dose escalated

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VT-122 high dose
Description: VT-122 high dose, dose escalated
Study: NCT01972269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-fentanyl
Description: 0.125% bupivacaine-fentanyl 5mcg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 2% lidocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 2% lidocaine
Study: NCT03491527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation of the resin cement without MTA
Description: Manipulation of the resin cement without MTA according to the manufacturer's recommendations.
Study: NCT01972269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: 2% lidocaine
Study: NCT00710320

Intervention type: PROCEDURE
Intervention: Covered and uncovered anesthesia induction
Description: We hypothesize that the core temperatures of:~1. the covered group during induction of general anesthesia will be greater by 0.5ºC than the uncovered group during induction of general anesthesia.~2. both groups, covered and uncovered, will be equal during surgery and post-operatively. In other words, due to the active warming procedures during surgery and post-operatively in the PICU, core temperatures of the uncovered group will catch up to the covered group.
Study: NCT03491527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fiber Post cimentation
Description: Insertion of the cement on the root canal and on post surface. Light-cured for 40 seconds on each surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fiber Post cimentation
Description: Insertion of the cement on the root canal and on post surface. Light-cured for 40 seconds on each surface.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Prepare
Description: Confection of a indirect crown prepare with diamand burs.
Study: NCT03012113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirabegron

Intervention type: OTHER
Group type: OTHER
Intervention: Short term mild cooling

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Study: NCT03491527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental Prepare
Description: Confection of a indirect crown prepare with diamand burs.
Study: NCT01889784

Intervention type: DEVICE
Group type: OTHER
Intervention: Phototherapy through light emitting diode (LED) - 300J
Description: The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
Study: NCT03996577

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group will be given the same volume of saline.
Study: NCT03867942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monolayer group
Description: Monolayered combination of gemigliptin and rosuvastatin
Study: NCT03491527

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dental impression
Description: Dental impression whith silicone.
Study: NCT01889784

Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo phototherapy - 300J
Description: The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.

Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo phototherapy - 300J
Description: The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
Study: NCT04497779

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and/or nasopharyngeal swabs

Intervention type: OTHER
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Donors and recipients have their medical records reviewed.

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03762655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuro-Spinal Scaffold
Description: The investigational product (Neuro-Spinal ScaffoldTM or Scaffold) is a porous bioresorbable polymer scaffold comprised of a synthetic biomaterial, poly(lactic-co-glycolic acid)-b-poly(L-lysine) (PLGA-PLL). The Scaffold is cylindrical in shape (3 mm diameter) and is available is three lengths (6 mm, 8 mm, 10 mm) for optimal fit in the intraspinal lesion cavity.~Based upon pre-clinical testing, the Scaffold is expected to be resorbed from the site of implant within 4 to 8 weeks.
Study: NCT03205059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LST MS curriculum+ Bullying/Cyberbulling serious game
Description: The prevention materials for middle school bullying and cyberbullying will (1) utilize both interactive classroom sessions and serious/educational games (digital games used to educate in an entertaining format); (2) positively change social norms surrounding bullying and cyberbulling; (3) challenge positive expectancies about bullying and cyberbullying; (4) enhance protective factors by building social, self-regulation, and relationship skills throughout the interactive learning and behavioral rehearsal; and (5) include booster sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LST MS curriculum
Description: The evidence-based LifeSkills Training program has been successfully used as a universal, school-based substance abuse and violence prevention program for middle school youth. The goals of the LST program are to teach youth the personal self-management skills, social skills, and other life skills needed to successfully resist drug and alcohol use, navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
Study: NCT03867942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monolayer group
Description: Monolayered combination of gemigliptin and rosuvastatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilayer group
Description: Bilayered combination of gemigliptin and rosuvastatin
Study: NCT02817165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic (BioK+)
Description: Probiotic (BioK+) with 3 stains of Lactobacillus
Study: NCT03867942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bilayer group
Description: Bilayered combination of gemigliptin and rosuvastatin
Study: NCT01411605

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: 12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).~Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol.
Study: NCT01896609

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reiferon Retard in Arm 1
Description: Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reiferon Retard in Arm 1
Description: Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Reiferon Retard in Arm 1
Description: Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
Study: NCT00607399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGX523 Capsules
Description: This is a dose escalation study
Study: NCT04691908

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: QazCovid-in®-vaccine against COVID-19
Description: QazCovid-in® (inactivated) Vaccine manufactured by Research Institute for Biological Safety Problems Republic of Kazakhstan
Study: NCT02817165

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
Study: NCT04691908

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (sodium chloride buffs, solvent for the preparation of dosage forms for injection 0.9%)
Study: NCT04266756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag matrix tablet
Description: Participants will receive single oral dose of Selexipag tablet(with fast, medium, and slow release profile) under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag encapsulated pellets
Description: Participants will receive single oral dose of Selexipag pellets (with fast, medium, and slow release profile) under fasted condition.
Study: NCT02984566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kilovoltage Intrafraction Monitoring
Description: KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
Study: NCT00778700

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Cream with no active drug
Study: NCT02535689

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03188744

Intervention type: OTHER
Intervention: Assessment of the pelvic floor function
Description: Vaginal palpation and perineometry.
Study: NCT04266756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag Immediate-release (IR) tablet
Description: Participants will receive Selexipag immediate-release tablet orally under fasted condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selexipag Immediate-release (IR) tablet
Description: Participants will receive Selexipag immediate-release tablet orally under fasted condition.
Study: NCT02861482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bakri Balloon
Description: Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemabate
Description: using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon